Clinical Manifestations and Treatment of Churg-Strauss Syndrome

Rheumatic Disease Clinics of North America

Volumn 36, Issue 3, 2010, Pages 527-543

  Baldini, Chiara ^a   Talarico, Rosaria ^a   Della Rossa, Alessandra ^a   Bombardieri, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

ANCA; Churg Strauss syndrome; Clinical manifestations; Therapy; Vasculitis

Indexed keywords

ADALIMUMAB; ALLERGEN; ALPHA INTERFERON; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; INFLIXIMAB; MEPOLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OMALIZUMAB; PREDNISOLONE; PREDNISONE; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ALLERGIC RHINITIS; ANCA ASSOCIATED VASCULITIS; ASTHMA; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPEREOSINOPHILIA; INCIDENCE; KIDNEY DISEASE; LOW DRUG DOSE; LUNG LAVAGE; NERVE BIOPSY; NEUROLOGIC DISEASE; NOSE POLYP; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHENOTYPE; PLASMAPHERESIS; PLEURA EFFUSION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; SKIN DISEASE; SURAL NERVE; SURVIVAL RATE; SYMPTOMATOLOGY; VASCULITIS;

ADRENAL CORTEX HORMONES; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ASTHMA; CHURG-STRAUSS SYNDROME; DRUG THERAPY, COMBINATION; EOSINOPHILIA; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION;

EID: 77955238741     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2010.05.003     Document Type: Review

References (77)

1. Churg J., Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951, 27(2):277-301.
2. Masi A.T., Hunder G.G., Lie J.T., et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990, 33(8):1094-1100.
3. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
4. Watts R.A., Scott D.G. Recent developments in the classification and assessment of vasculitis. Best Pract Res Clin Rheumatol 2009, 23(3):429-443.
5. Luqmani R.A. Towards diagnostic criteria for the ANCA-associated vasculitides. Clin Exp Rheumatol 2007, 25(1 Suppl 44):S57.
6. Pagnoux C., Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes?. Curr Opin Rheumatol 2010, 22(1):21-28.
7. Chen M., Kallenberg C.G. New advances in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol 2009, 27(1 Suppl 52):S108-S114.
8. Phillip R., Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008, 26(5 Suppl 51):S94-104.
9. Gatenby P.A., Lucas R.M., Engelsen O., et al. Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation?. Arthritis Rheum 2009, 61(10):1417-1424.
10. Mohammad A.J., Jacobsson L.T., Mahr A.D., et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007, 46(8):1329-1337.
11. Mahr A., Guillevin L., Poissonnet M., et al. Prevalence of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004, 51:92-99.
12. Sinico R.A., Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol 2009, 23(3):355-366.
13. Kahn J.E., Blétry O., Guillevin L. Hypereosinophilic syndromes. Best Pract Res Clin Rheumatol 2008, 22(5):863-882.
14. Chumbley L.C., Harrison E.G., DeRemee R.A. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 1977, 52(8):477-484.
15. Lanham J.G., Elkon K.B., Pusey C.D., et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984, 63(2):65-81.
16. Gaskin G., Clutterbuck E.J., Pusey C.D. Renal disease in the Churg-Strauss syndrome. Diagnosis, management and outcome. Contrib Nephrol 1991, 94:58-65.
17. Abu-Shakra M., Smythe H., Lewtas J., et al. Outcome of polyarteritis nodosa and Churg-Strauss syndrome. An analysis of twenty-five patients. Arthritis Rheum 1994, 37:1798-1803.
18. Reid A.J., Harrison B.D., Watts R.A., et al. Churg-Strauss syndrome in a district hospital. QJM 1998, 91(3):219-229.
19. Lhote F., Cohen P., Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus 1998, 7(4):238-258.
20. Guillevin L., Cohen P., Gayraud M., et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999, 78(1):26-37.
21. Gayraud M., Guillevin L., le Toumelin P., French Vasculitis Study Group, et al. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44(3):666-675.
22. Solans R., Bosch J.A., Pérez-Bocanegra C., et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001, 40(7):763-771.
23. Della Rossa A., Baldini C., Tavoni A., et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 2002, 41(11):1286-1294.
24. Keogh K.A., Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003, 115(4):284-290.
25. Sablé-Fourtassou R., Cohen P., Mahr A., French Vasculitis Study Group, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005, 143(9):632-638.
26. Sinico R.A., Di Toma L., Maggiore U., et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005, 52(9):2926-2935.
27. Oh M.J., Lee J.Y., Kwon N.H., et al. Churg-Strauss syndrome: the clinical features and long-term follow-up of 17 patients. J Korean Med Sci 2006, 21(2):265-271.
28. Churg A., Brallas M., Cronin S.R., et al. Formes frustes of Churg-Strauss syndrome. Chest 1995, 108(2):320-323.
29. Nathani N., Little M.A., Kunst H., et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008, 63(10):883-888.
30. Bibby S., Healy B., Steele R., et al. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010, 65(2):132-138.
31. Puéchal X., Rivereau P., Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med 2008, 19(5):364-366.
32. Thomson C.C., Tager A.M., Weller P.F. Clinical problem-solving. More than your average wheeze. N Engl J Med 2002, 346(6):438-442.
33. Papadimitraki E.D., Kyrmizakis D.E., Kritikos I., et al. Ear-nose-throat manifestations of autoimmune rheumatic diseases. Clin Exp Rheumatol 2004, 22(4):485-494.
34. Bottero P., Bonini M., Vecchio F., et al. The common allergens in the Churg-Strauss syndrome. Allergy 2007, 62(11):1288-1294.
35. Eustace J.A., Nadasdy T., Choi M. Disease of the month. The Churg Strauss syndrome. J Am Soc Nephrol 1999, 10(9):2048-2055.
36. Del Pero M.M., Sivasothy P. Vasculitis of the upper and lower airway. Best Pract Res Clin Rheumatol 2009, 23(3):403-417.
37. Kim Y.K., Lee K.S., Chung M.P., et al. Pulmonary involvement in Churg-Strauss syndrome: an analysis of CT, clinical, and pathologic findings. Eur Radiol 2007, 17(12):3157-3165.
38. Zhang W., Zhou G., Shi Q., et al. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 2009, 27(1 Suppl 52):S65-S69.
39. Ferro J.M. Vasculitis of the central nervous system. J Neurol 1998, 245(12):766-776.
40. Lamprecht P., Holle J., Gross W.L. Update on clinical, pathophysiological and therapeutic aspects in ANCA-associated vasculitides. Curr Drug Discov Technol 2009, 6(4):241-251.
41. Crowson A.N., Mihm M.C., Magro C.M. Cutaneous vasculitis: a review. J Cutan Pathol 2003, 30(3):161-173.
42. Rashtak S., Pittelkow M.R. Skin involvement in systemic autoimmune diseases. Curr Dir Autoimmun 2008, 10:344-358.
43. Jennette J.C., Falk R.J. The role of pathology in the diagnosis of systemic vasculitis. Clin Exp Rheumatol 2007, 25(1 Suppl 44):S52-S56.
44. Marmursztejn J., Vignaux O., Cohen P., et al. Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. Clin Exp Rheumatol 2009, 27(1 Suppl 52):S70-S76.
45. Dennert R.M., van Paassen P., Schalla S., et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010, 62(2):627-634.
46. Pagnoux C., Mahr A., Cohen P., et al. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 2005, 84(2):115-128.
47. Sharma M.C., Safaya R., Sidhu B.S. Perforation of small intestine caused by Churg-Strauss syndrome. J Clin Gastroenterol 1996, 23(3):232-235.
48. Boggi U., Mosca M., Giulianotti P.C., et al. Surviving catastrophic gastrointestinal involvement due to Churg-Strauss syndrome: report of a case. Hepatogastroenterology 1997, 44(16):1169-1171.
49. Sinico R.A., Di Toma L., Maggiore U., et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006, 47(5):770-779.
50. De Salvo G., Li Calzi C., Anastasi M., et al. Branch retinal vein occlusion followed by central retinal artery occlusion in Churg-Strauss syndrome: unusual ocular manifestations in allergic granulomatous angiitis. Eur J Ophthalmol 2009, 19(2):314-317.
51. Allenbach Y., Seror R., Pagnoux C., French Vasculitis Study Group, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009, 68(4):564-567.
52. Kallenberg C.G. Churg-Strauss syndrome: just one disease entity?. Arthritis Rheum 2005, 52(9):2589-2593.
53. Vaglio A., Martorana D., Maggiore U., Secondary and Primary Vasculitis Study Group, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007, 56(9):3159-3166.
54. Guilpain P., Auclair J.F., Tamby M.C., et al. Serum eosinophil cationic protein: a marker of disease activity in Churg-Strauss syndrome. Ann N Y Acad Sci 2007, 1107:392-399.
55. Roufosse F. Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica 2009, 94(9):1188-1193.
56. Pugliese N., Bruzzone M., Della Rossa A., et al. Churg-Strauss vasculitis and idiopathic hypereosinophyl syndrome: role of molecular biology in the differential diagnosis of hypereosinophyl syndrome. Reumatismo 2008, 60(2):120-124.
57. Tefferi A., Gotlib J., Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010, 85(2):158-164.
58. Manganelli P., Fietta P., Carotti M., et al. Respiratory system involvement in systemic vasculitides. Clin Exp Rheumatol 2006, 24(2 Suppl 41):S48-S59.
59. Bourgarit A., Le Toumelin P., Pagnoux C., French Vasculitis Study Group, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005, 84(5):323-330.
60. Mukhtyar C., Flossmann O., Hellmich B., European Vasculitis Study Group (EUVAS), et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008, 67(7):1004-1010.
61. Guillevin L. Advances in the treatments of systemic vasculitides. Clin Rev Allergy Immunol 2008, 35(1-2):72-78.
62. Metzler C., Hellmich B., Gause A., et al. Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004, 22(6 Suppl 36):S52-S61.
63. Ribi C., Cohen P., Pagnoux C., French Vasculitis Study Group, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008, 58(2):586-594.
64. Guillevin L., Cohen P., Mahr A., et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003, 49(1):93-100.
65. Jayne D., Rasmussen N., Andrassy K., European Vasculitis Study Group, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349(1):36-44.
66. Pagnoux C., Guillevin L. How can patient care be improved beyond medical treatment?. Best Pract Res Clin Rheumatol 2005, 19(2):337-344.
67. Taniguchi M., Tsurikisawa N., Higashi N., et al. Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int 2007, 56(2):97-103.
68. Metzler C., Schnabel A., Gross W.L., et al. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008, 26(3 Suppl 49):S35-S40.
69. Hellmich B., Gross W.L. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004, 5(1):25-35.
70. Roccatello D., Baldovino S., Alpa M., et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008, 26(3 Suppl 49):S67-S71.
71. Arbach O., Gross W.L., Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002, 206(5):496-501.
72. Bouldouyre M.A., Cohen P., Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 2009, 68(4):606.
73. Walsh G.M. Mepolizumab and eosinophil-mediated disease. Curr Med Chem 2009, 16(36):4774-4778.
74. Giavina-Bianchi P., Kalil J. Omalizumab administration in Churg-Strauss syndrome. Eur J Intern Med 2009, 20(6):e139.
75. Spina M.F., Miadonna A. Role of omalizumab and steroids in Churg-Strauss syndrome. J Allergy Clin Immunol 2009, 124(3):600-601.
76. Pabst S., Tiyerili V., Grohé C. Apparent response to anti-IgE therapy in two patients with refractory " forme fruste" of Churg-Strauss syndrome. Thorax 2008, 63(8):747-748.
77. Kahn J.E., Grandpeix-Guyodo C., Marroun I., et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010, 125(1):267-270.